On September 30, ASYMCHEM rose 4.26% in regular trading, trading at HK$166.3/share, with turnover of HK$19.85 million. The gain was driven by a combination of corporate governance updates and sustained momentum across the CRO/CDMO sector.
On the corporate front, the company held its fifth board of directors' fifteenth meeting on September 28, unanimously approving a charter revision proposal. The amendment reflects the completion of the registration of 2,436,500 restricted A-shares under the company's restricted stock incentive plan, with 1,285,200 shares newly issued and 1,151,300 shares sourced from prior buybacks. The registered capital will increase from RMB 360.66 million to RMB 361.95 million, subject to shareholder approval at an extraordinary general meeting scheduled for October 20.
At the industry level, the CRO/CDMO sector continues to benefit from robust innovative drug demand and accelerating AI-driven drug development commercialization. Sector-wide first-half results validated the high-growth trajectory, with domestic CXO companies posting aggregate revenue and net profit growth of 24.5% and 52.7% year-over-year respectively, while multiple leading firms raised full-year guidance. ASYMCHEM itself recently passed a U.S. FDA pre-approval inspection at its chemical macromolecule facility, further reinforcing its compliance credentials.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments